Ann: Letter to IMUOA & IMUOB Option Share Holders, page-23

From the talks to Lesley and Prof U Wiedermann I assume the following scenario:

IMU wants to get the drugs on the markets, therefore partnership is the aim.

But I wouldn't be surprised in case of a t/o offer to good to be refused that IMU sells the current IP and restarts, like PH with Vaxinia, with the next generation of B-cell / OV. In Vienna and at some German universities researchers working as well on their on B-cell tech - maybe a reason for the appointment of Rita - , the B-cell word is spreading, just hasn't hit the commercial market yet.

We just need the " beautiful " ph2 - results, that could trigger a B-cell tech mania.

Time will tell.

GLTA sufferers and holders.